BRAF and melanoma: Our study cohorts include heavily pre-treated patients (e.g., received ≥2 previous systemic therapies, pre-exposed to both anti-PD-1 and anti-CTLA4 ICIs), with an aggressive melanoma disease (e.g., characterized by elevated LDH and BRAF mutated status) and high rates of CNS involvement (e.g., M1c disease).